Biotechnology
US biopharma companies Fulcrum Therapeutics and Slate Medicines have agreed to combine in an all-stock merger, with the resulting entity operating as Slate Medicines, Inc. and trading on Nasdaq under the ticker "SLTE," the companies announced Monday. 17 August 2026
Biotechnology
US metabolic health company Skye Bioscience and Redx Pharma, a UK based, privately-held clinical-stage biotechnology company focused on developing novel, small molecule, targeted medicines for fibrotic disease, have entered into a definitive transaction agreement. 14 August 2026
Pharmaceutical
USA-based Sentynl Therapeutics and Mereo BioPharma Group have entered into an option and license agreement for the US commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). 12 August 2026
Pharmaceutical
Donald Trump signed an executive order on Monday recommending that American children be routinely immunized against 11 diseases rather than the 18 covered by the US Centers for Disease Control and Prevention's (CDC) 2024 schedule, and that the combined measles, mumps and rubella (MMR) vaccine be split into three single-disease shots. 11 August 2026
Biotechnology
Ireland-headquartered Jazz Pharmaceuticals has entered into a definitive agreement to acquire privately-held US biotech Actio Biosciences with the aim of expanding its epilepsy portfolio. 10 August 2026
Most Read
Features
Pharmaceutical
USA-based contract research organization's new chief executive tells The Pharma Letter that a sharper focus on regulated safety assessment, deeper client data-sharing and non-animal testing methods will define her tenure. 17 August 2026
Pharmaceutical
The Russian subsidiary of the Indian pharmaceutical company Dr Reddy's Laboratories received the rights to three gynecological drugs from the local drugmaker Vertex with the aim to significantly strengthen its presence in that segment of the market, reports The Pharma Letter’s local correspondent. 14 August 2026
Pharmaceutical
For decades, the pharmaceutical industry has largely focused on discovering new molecules. Laxxon Medical believes the next major innovation may instead come from rethinking how those medicines are delivered. 10 August 2026
Pharmaceutical
An Expert View from Ella Green, Maggie Gisseleire, and Laura Johnson, Carpmaels & Ransford. 7 August 2026
Company Spotlight
A Danish clinical-stage TechBio company using its proprietary AI-Immunology platform to design therapeutic vaccines for cancer and infectious disease, with a pipeline spanning personalized, off-the-shelf, and bacterial vaccine candidates.
Recent news
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today published a position paper clarifying how microbiome-based medicines can be made available for patients in the UK, encouraging developers to pursue UK licencing pathways for this emerging class of therapies. 18 August 2026
Biotechnology
US AI-native biotechnology company Aizen Therapeutics has announced a multi-program collaboration with a fellow San Diego-based, public biotech to design oral peptide therapeutics using its DaX foundation model. 18 August 2026
Pharmaceutical
Danish dermatology specialist LEO Pharma today announces that it has entered into an agreement to acquire worldwide rights to dersimelagon from Japanese drugmaker Tanabe Pharma. 18 August 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals has voluntarily terminated an early-stage study of REGN7041, an experimental anti-CD3 monoclonal antibody being developed for active non-infectious uveitis affecting the back of the eye, after judging that the benefit-risk profile no longer supported continuing. 18 August 2026
Pharmaceutical
USA-based Femasys, a biomedical innovator focused on fertility and permanent birth control solutions, has secured $30 million in financing, with potential proceeds reaching up to $90 million upon the full cash exercise of warrants. 18 August 2026
Refine search
In Brief
Pharmaceutical
6 August 2026 There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a potential deal, a senior source close to the matter told Reuters on Wednesday, quashing the prospect of a mooted mega merger between the drugmakers.
Pharmaceutical
7 July 2026 Codis has agreed to acquire Catalent Pharma Solutions’ Nottingham, UK, facility, expanding its contract development and manufacturing organization (CDMO) capabilities in oral solid dose development and manufacturing. The deal is expected to close in the third quarter of 2026, subject to customary conditions.
Conferences
25 August 2026 27 August 2026 Seoul, South Korea, COEX Convention & Exhibition Center
28 August 2026 31 August 2026 Munich, Germany, Munich Trade Fair Centre
30 August 2026 2 September 2026 Montreal, Canada, Montréal Congress Center
31 August 2026 4 September 2026 Geneva, Switzerland, International Conference Centre Geneva
5 September 2026 9 September 2026 Barcelona, Spain, Fira Gran Via
7 September 2026 11 September 2026 Antwerp, Belgium
More Events
Insights
Pharmaceutical
For decades, the pharmaceutical industry has largely focused on discovering new molecules. Laxxon Medical believes the next major innovation may instead come from rethinking how those medicines are delivered. 10 August 2026
Pharmaceutical
An Expert View from Ella Green, Maggie Gisseleire, and Laura Johnson, Carpmaels & Ransford. 7 August 2026
Generics
The Russian government has opposed the recently made proposal to grant the domestic patent service Rospatent the right to pre-trial block the distribution of drugs whose release infringes patents on original drugs, reports The Phara Letter's local correspondent. 6 August 2026
Pharmaceutical
Russia is considering increasing drug procurements against hepatitis C. According to official data, governmental procurements of such drugs over the last year and a half has reached almost 50 billion roubles ($619.2 million), reports The Pharma Letter’s local correspondent. 5 August 2026
Pharmaceutical
In July 2025 the White House sent letters to 17 large drugmakers asking them to match, for American patients, the lowest prices they charge in other wealthy nations. A year on, all 17 have signed "most-favored-nation" (MFN) pricing deals. The administration says the group accounts for about 86% of the branded US market. 4 August 2026
Pharmaceutical
India’s pharmaceutical sector is undergoing a structural shift, with diabetes therapies and cardiac care driving growth well above the broader market. 3 August 2026
Pharmaceutical
Medicines regulators recorded a relatively quiet week in the seven days to 3 August 2026, with the USA accounting for the confirmed activity. 3 August 2026
One to Watch Companies
One to watch
A neurology-focused specialty pharmaceutical company headquartered in Frankfurt am Main, Germany. It is active internationally, commercializing products across a broad set of markets through a mix of affiliates and partners.
One to watch
A biotech company focused on the development of a p300/CBP inhibitor to treat specific cancer types.
One to watch
A clinical-stage biotechnology company developing novel T-cell engagers for autoimmune and inflammatory diseases, Candid Therapeutics launched in 2024 with $370 million in Series A financing and agreed to a $2.2 billion acquisition by UCB in May 2026.
One to watch
A privately-held French biotech advancing a clinical pipeline of gamma delta T-cell-focused antibodies for cancer and autoimmune diseases.
Boardroom
Pharmaceutical
USA-based Femasys, a biomedical innovator focused on fertility and permanent birth control solutions, has secured $30 million in financing, with potential proceeds reaching up to $90 million upon the full cash exercise of warrants. 18 August 2026
Biotechnology
US clinical-stage biotech Neumora Therapeutics on Friday announced that Joshua Pinto has been appointed as chief executive (CEO) and a member of the board of directors. 17 August 2026
Biotechnology
US clinical-stage biotech Olema Oncology has announced the appointment of Jason O’Byrne, chief financial officer. (CFO). 14 August 2026
Pharmaceutical
Pace, a science and technology company, has appointed Andrew (Andy) Fenny as president of Pace Life Sciences, the organization’s life sciences division, to lead the business into its next phase of strategic growth with a focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle. 14 August 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze